• About Us
    • Contact Us
    • Login
    • ObGFirst
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • COVID-19
About Us Contact Us Login ObGFirst
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • COVID-19
Grand Rounds

Fluoroquinolones and Risk for Aortic Aneurysm: Results from a Large US Cohort Study

image_pdfFavoriteLoadingFavorite

BACKGROUND AND PURPOSE:

  • International studies have indicated that there may be a link between fluoroquinolone use and increased risk of aortic aneurysm and dissection
  • FDA has issued a warning, but data is limited in the US, including a determination of which patients are at highest risk
  • Newton et al. (JAMA Surg, 2021) assessed aortic aneurysm and dissection risks in a heterogeneous US population following fluoroquinolone use

METHODS:

  • Retrospective cohort study
  • Data source
    • MarketScan health insurance claims
  • Participants
    • Commercially insured individuals
    • 18 to 64 years
    • Filled a prescription for fluoroquinolones or a comparator antibiotic from 2005 to 2017
    • Exclusion: Previous aortic aneurysm or dissection | Recent antibiotic exposure | Recent hospitalization
  • Exposure
    • Outpatient fill of an oral fluoroquinolone
    • Comparator antibiotic | E.g., amoxicillin-clavulanate, azithromycin, cephalexin, clindamycin, and sulfamethoxazole-trimethoprim
  • Study design
    • Cox regression was used to estimate the association between fluoroquinolone fill and 90-day aneurysm incidence
    • Interaction terms were used to assess the association of known risk factors (ie, sex, age, and comorbidities) with aneurysm after fluoroquinolone use
  • Primary outcomes
    • 90-day incidence of aortic aneurysm and dissection

RESULTS:

  • 27,827,254 US adults | 47,596,545 antibiotic episodes
    • Fluoroquinolone fills: 19% | Comparator antibiotics: 81%
    • Median age of patient
      • Fluoroquinolone: 47 years; 61.3% women
      • Comparator antibiotics: 43 years; 59.5% women
  • 90-day incidence of newly diagnosed aneurysm without taking in to account other risk factors
    • After fluoroquinolones: 7.5 cases per 10,000 fills
    • After comparators: 4.6 cases per 10,000 fills
  • After weighting for demographic characteristics and comorbidities, fluoroquinolone fills were associated with increased incidence of aneurysm formation
    • Hazard ratio (HR) 1.20 (95% CI, 1.17 to 1.24)
  • Compared with comparator antibiotics, fluoroquinolone fills were associated with increased 90-day incidence of
    • Abdominal aortic aneurysm: HR 1.31 (95% CI, 1.25 to 1.37)
    • Iliac artery aneurysm: HR 1.60 (95% CI, 1.33, to 1.91)
    • Other abdominal aneurysm: HR 1.58 (95% CI, 1.39 to 1.79)
  • Adults with fluoroquinolone fills were more likely to undergo aneurysm repair
    • HR 1.88 (95% CI, 1.44 to 2.46)
  • When stratified by age, all adults 35 years or older appeared at increased risk (P = 0.04)
    • 18 to 34 years: HR 0.99 (95% CI, 0.83 to 1.18)
    • 35 to 49 years: HR 1.18 (95% CI, 1.09 to 1.28)
    • 50 to 64 years: HR 1.24 (95% CI ,1.19 to 1.28)
  • Minor differences seen when above data stratified by
    • Sex | Diabetes | Hypertension | Hyperlipidemia

CONCLUSION:

  • Fluoroquinolones were associated with an increase in aortic aneurysms in US adults
  • This increased risk was found regardless of sex, comorbidities, and age suggesting that this drug class poses a risk in healthy and unhealthy individuals
  • Limitations of this study included
    • Lack of confirmation whether medications were actually taken
    • Inability to identify patients who may have had an undiagnosed aneurysm prior to study inclusion (i.e., the drug aggravated a pre-existing condition)
  • The authors state

Contextualizing these data, we believe that the current US FDA black box warnings are warranted but may need to be expanded to include younger adults with other risk factors

Learn More – Primary Sources:

Association of Fluoroquinolone Use With Short-term Risk of Development of Aortic Aneurysm

Now You Can Get Mobile-Friendly ObG Clinical Research Summaries with ObGFirst

ObGFirst® – Try It Free! »

image_pdfFavoriteLoadingFavorite
< Previous
All Grand Rounds Posts
Next >

Related ObG Topics:

Are Fluoroquinolones Truly Associated with Increased Risk of Aortic Dissection?
Could Quinolone Exposure Increase Risk to Fetus?

Sections

  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • Grand Rounds
  • My Bookshelf
  • COVID-19

Are you an
ObG Insider?

Get specially curated clinical summaries delivered to your inbox every week for free

  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Already a Member of ObGFirst®?

Please log in to ObGFirst to access the 2T US Atlas

Password Trouble?

Not an ObGFirst® Member Yet?

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!
ObGFirst Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site